NCT06982040

Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Primary IgA Nephropathy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade. It is being clinically developed for the treatment of primary IgA nephropathy The main objectives of the study were to assess the efficacy and safety of NTQ5082 capsules in the treatment of patients with primary IgA nephropathy.

Conditions

• Primary IgA Nephropathy

Interventions

Type	Name	Description
DRUG	NTQ5082 capsules 100 mg	NTQ5082 capsules 100 mg
DRUG	NTQ5082 capsules 200 mg	NTQ5082 capsules 200 mg
DRUG	NTQ5082 capsules 300 mg	NTQ5082 capsules 300 mg
DRUG	Placebo	Placebo

Timeline

• Start date: 2025-05-01
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-05-21
• Last updated: 2025-05-21